MicrodosingMedicinal Chemistry & Drug DevelopmentLSDPsilocybin

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research

We don't know much about the effects of microdosing or have even defined it rigorously. Kuypers and colleagues (2019) ask the questions and take the first step in building a framework for a more scientific microdosing study. Microdosing is defined as the 1) use of a low dose below the perceptual threshold that does not impair ‘normal’ functioning of an individual, 2) a procedure that includes multiple dosing sessions, and 3) with the intention to improve well-being and enhance cognitive and emotional processes.

Ask Blossom about this paper

Authors

  • Gitte Knudsen
  • David Nutt
  • Kim Kuypers

Published

Journal of Psychopharmacology
meta Study

Abstract

Background

In the past few years, the issue of ‘microdosing’ psychedelics has been openly discussed in the public arena where claims have been made about their positive effect on mood state and cognitive processes such as concentration. However, there are very few scientific studies that have specifically addressed this issue, and there is no agreed scientific consensus on what microdosing is.

Aim

This critique paper is designed to address questions that need to be answered by future scientific studies and to offer guidelines for these studies.Approach: Owing to its proximity for a possible approval in clinical use and short-lasting pharmacokinetics, our focus is predominantly on psilocybin. Psilocybin is allegedly, next to lysergic acid diethylamide (LSD), one of the two most frequently used psychedelics to microdose. Where relevant and available, data for other psychedelic drugs are also mentioned.

Conclusion

It is concluded that while most anecdotal reports focus on the positive experiences with microdosing, future research should also focus on potential risks of (multiple) administrations of a psychedelic in low doses. To that end, (pre)clinical studies including biological (e.g. heart rate, receptor turnover and occupancy) as well as cognitive (e.g. memory, attention) parameters have to be conducted and will shed light on the potential negative consequences microdosing could have.

Unlocked with Blossom Pro

Research Summary of 'Microdosing psychedelics: More questions than answers? An overview and suggestions for future research'

Editorial

βBlossom's Take

This commentary is useful because it stops microdosing from drifting into vague enthusiasm and asks what still needs defining. Its main contribution is conceptual, setting a stricter working definition and pointing out that repeated low-dose use should be studied for risks as well as claimed benefits.

Study Details

Cited By (58)

Papers in Blossom that reference this study

Psychedelic-induced hypomania and mania: a systematic review and meta-analysis

Eskinazi, M., Nasserdine, R., Cusin, R. M. et al. · Molecular Psychiatry (2026)

LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial

Daldegan-Bueno, D., Donegan, C. J., Sumner, R. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2026)

1 cited
LSD microdosing in major depressive disorder: results from an open-label trial

Daldegan-Bueno, D., Donegan, C. J., Sumner, R. L. et al. · Neuropharmacology (2026)

4 cited
Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials

Prochazkova, L., van Elk, M., Marschall, J. et al. · Neuropsychopharmacology (2025)

7 cited
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults A Randomized Clinical Trial

Mueller, L., de Jesus, N. M. S., Schmid, Y. et al. · JAMA Psychiatry (2025)

11 cited
Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice

Effinger, D. P., Schalk, S. S., King, J. L. et al. · ACS Pharmacology and Translational Science (2025)

2 cited
Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use

Syed, O. A., Petranker, R., Fewster, E. C. et al. · Journal of Psychoactive Drugs (2024)

7 cited
Expectancy effects in psychedelic trials

Szigeti, B., Heifets, B. D. · Biological Psychiatry (2024)

58 cited
Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine

Murray, C., Frohlich, J, Haggarty, C. J., Tare, I. et al. · Neuropsychopharmacology (2024)

29 cited
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats

Kiilerich, K. F., Lorenz, J., Scharff, M. B. et al. · Molecular Psychiatry (2023)

43 cited
Show all 58 papers
Psychedelic Intimacy: Altered States of Consciousness in Romantic Relationships

Neubert, J. J., Anderson, K., Mason, N. L. · Psyarxiv (2023)

Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study

Cavarra, M., Mason, N. L., Kuypers, K. P. C. et al. · European Journal of Pain (2023)

27 cited
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Tagen, M., Mantuani, D., Van Heerden, L. et al. · Journal of Psychopharmacology (2023)

39 cited
Microdosing psychedelics has no impact on cognitive function in naturalistic settings

Dinkelacker, J., Pop, I. · Journal of Clinical Psychiatry (2023)

2 cited
The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing

Szigeti, B., Nutt, D. J., Carhart-Harris, R. L. et al. · Scientific Reports (2023)

33 cited
Unlocking the self: Can microdosing psychedelics make one feel more authentic?

Pop, I., Dinkelacker, J. · Nordic Studies on Alcohol and Drugs (2023)

5 cited
Microdosing psychedelics - Does it have an impact on emodiversity?

Pop, I., Dinkelacker, J. · Journal of Psychedelic Studies (2023)

4 cited
Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial

Baumann, S., Carhart-Harris, R. L., Nutt, D. J. et al. · Psyarxiv (2022)

2 cited
A long trip into the universe: Psychedelics and space travel

Lerer, L. B., Varia, J. · Frontiers in Space Travel (2022)

2 cited
Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD

Cao, C., Barros-Álvarez, X., Kim, K. et al. · Neuron (2022)

152 cited
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives

Kaypak, A. C., Raz, A. · Transcultural Psychiatry (2022)

17 cited
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)

127 cited
Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics: A Critical Review

van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)

208 cited
A systematic literature review of clinical trials and therapeutic applications of ibogaine

Köck, P., Frölich, K., Walter, M. et al. · Journal of Substance Abuse Treatment (2022)

61 cited
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

Rootman, J. M., Kiraga, M., Kryskow, P. et al. · Scientific Reports (2022)

51 cited
Natural language signatures of psilocybin microdosing

Sanz, C., Cavanna, F., Muller, S. et al. · Psychopharmacology (2022)

18 cited
Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity

Barr, A. M., Huang, J., Pham, M. et al. · Frontiers in Psychiatry (2022)

19 cited
Psychedelic Cognition-The Unreached Frontier of Psychedelic Science

Balaet, M. · Frontiers in Neuroscience (2022)

27 cited
Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study

de Wit, H., Molla, H. M., Bershad, A. K. et al. · Addiction Biology (2022)

81 cited
Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT

Barker, S. A. · Psychopharmacology (2022)

59 cited
The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955 - 2021)

Polito, V., Liknaitzky, P. · Psyarxiv (2021)

2 cited
Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity

Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2021)

8 cited
Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials

Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)

20 cited
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

Rootman, J. M., Kryskow, P., Harvey, K. et al. · Scientific Reports (2021)

75 cited
From Psychiatry to Neurology: Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders

Nichols, C. D., Wiatr, K., Figiel, M. et al. · Journal of Neurochemistry (2021)

75 cited
Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults

Perry, C. M., Malina, M. · Psychopharmacology (2021)

73 cited
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Corrigan, K., Haran, M., Mccandliss, C. et al. · Irish Journal of Medical Science (2021)

74 cited
Exploring the relationship between microdosing, personality and emotional insight: A prospective study

Dressler, H. M., Bright, S. J., Polito, V. · Journal of Psychedelic Studies (2021)

12 cited
Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study

Van Elk, M., Fejer, G., Lempe, P. et al. · Psychopharmacology (2021)

53 cited
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)

152 cited
The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects

Olson, D. E. · ACS Pharmacology and Translational Science (2020)

326 cited
The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

128 cited
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · European Neuropsychopharmacology (2020)

120 cited
Pivotal Mental States

Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)

145 cited
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)

345 cited
Treatment of a Complex Personality Disorder Using Repeated Doses of LSD-A Case Report on Significant Improvements in the Absence of Acute Drug Effects

Müller, F., Mühlhauser, M., Holze, F. et al. · Frontiers in Psychiatry (2020)

31 cited
Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants

Zhang, D. Z., Holze, F., Liechti, M. E. et al. · Clinical Pharmacology and Therapeutics (2020)

63 cited
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)

238 cited
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review

Ona, G., Bouso, J. C. · Neuroscience and Biobehavioral Reviews (2020)

58 cited
Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · ACS Pharmacology and Translational Science (2020)

132 cited
The therapeutic potential of microdosing psychedelics in depression

Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)

82 cited
Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan

Carbonaro, T. M., Johnson, M. W., Griffiths, R. R. · Psychopharmacology (2020)

50 cited
Psychedelic Psychiatry’s Brave New World

Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)

322 cited
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.

Rosenbaum, D., Weissman, C. R., Anderson, T. et al. · Journal of Psychopharmacology (2020)

74 cited
Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders

Lea, T., Jungaberle, H., Schecke, H. et al. · Psychopharmacology (2020)

80 cited
Microdosing psychedelics: Motivations, subjective effects and harm reduction

Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)

115 cited
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

Family, N., Maillet, E. L., Williams, L. T. J. et al. · Psychopharmacology (2019)

141 cited
Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers

Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · Frontiers in Psychiatry (2019)

76 cited